New venture capitalist focusing on health technology makes its first investment in point-of-care analytics
Fepod's technology has been developed for years, e.g. with funding from Business Finland at Aalto University, and early clinical studies of the technology have been completed at HUS. The testing equipment consists of a standard smart phone, an affordable, small potentiostat, and mass-produced and disposable sampling sensors. The machine-learning algorithms being developed by Fepod will make it possible to expand the business into new areas as the analysis database grows.
“Almaral's significant investment will enable Fepod to take a step towards commercializing the technology. It allows us to begin the regulatory approval processes in both the United States and the EU. In addition to the capital we have received, we are very impressed with Almaral's diverse team, which has a proven track record of building Finnish innovations into global success stories,” says Jussi Pyysalo, the founder and CEO of Fepod.
Almaral currently has about ten investment targets under active evaluation. The private equity investor’s new, holistic operating model has attracted a lot of interest, but rather than quantity, the company wants to focus on quality.
“Fepod was selected as our first investment because we recognized the company's ambition and business opportunities. I am convinced that our expertise perfectly complements Fepod’s goals. We believe that the development of electrochemical point-of-care analytics will save huge amounts of money and lives worldwide,” says the CEO of Almaral, Dr. Maria Severina.
Fepod Oy Ltd was founded in February 2022 to commercialize the novel diagnostics method based on nano-carbon sensors, portable potentiostats and machine-learning algorithms. The founding team consists of the original core team from Aalto University as well as two co-founders who complement their skill sets.
Almaral invests in early-stage biotechnology and life science startups. Besides investment, Almaral offers guidance in risk management, building up long-term strategies, budgeting, setting up operational functions, legal support, setting up early-stage sales and marketing functions, and commercialization.
Contact:
Fepod:
Jussi Pyysalo, CEO
jussi.pyysalo@fepod.com
+358 400 789328
Almaral:
Maria Severina, CEO
info@almaral.eu
+358 405 540127
About Hansdotter Oy
Almaral invests in early-stage biotechnology and life sciences startups. Along with investment Almaral offers guidance in risk management, building up long term strategies, budgeting, setting up operational functions, legal support, setting up early-stage sales and marketing functions, and commercialization.
www.almaral.eu
Subscribe to releases from Hansdotter Oy
Subscribe to all the latest releases from Hansdotter Oy by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Hansdotter Oy
Mainostoimisto Hansdotterin toimitusjohtajaksi digiosaaja Tatu Koivu3.6.2024 10:11:39 EEST | Tiedote
Koko kuusivuotisen taipaleensa tasaisesta ja kannattavasti kasvanut mainostoimisto Hansdotter vaihtaa toimitusjohtajaa. Uudeksi toimitusjohtajaksi 1.6. alkaen on nimitetty yrityksen menestyksekkäästä digiloikasta vastannut operatiivinen johtaja Tatu Koivu. Hän näkee päätehtävänään asiakkaista ja ihmisistä välittämisen.
Mainostoimisto Hansdotterin oma suljettu tekoäly opetetaan asiakkaiden tavoille29.2.2024 09:00:00 EET | Tiedote
Suljettu tekoäly mahdollistaa sen turvallisen käytön myös luovan markkinointiviestinnän apuna. Hansdotterin omaa tekoälyä ja sen mahdollisuuksia yhdessä työntekijöiden kanssa kehittää yrityksen tekoälyasiantuntija Eeva Rauramo.
The Planet Company ja Hansdotter tuovat yhdessä yritysten vastuullisuustyöhön mitattavuutta ja vaikuttavuutta11.10.2023 11:50:49 EEST | Tiedote
The Planet Companyn ainutlaatuinen toimintamalli auttaa yrityksiä tekemään vastuullisuuspuheista mitattavia tekoja sekä saamaan riippumattoman vastuullisuusasiantuntijan arvion teoilleen. Markkinointiviestintätoimisto Hansdotter taas auttaa kertomaan vastuullisuusteoista vaikuttavasti sekä sisäisille että ulkoisille kohderyhmille.
Almaralilta merkittävä sijoitus syöpädiagnostiikkaa kehittävälle Genomillille5.9.2023 09:55:53 EEST | Tiedote
Almaral on tehnyt huomattavan pääomasijoituksen syöpädiagnostiikan edelläkävijänä tunnetulle Genomillille. Sijoitus on Almaralilta rohkea ja ennakkoluuloton investointi tarkkuusdiagnostiikan tulevaisuuteen.
A rare new type of ecosystem for startup growth architecture and funding is born in Finland26.4.2023 15:03:46 EEST | Press release
Finland has long been one of the most interesting markets for startup investors. However, an organization focused on helping founders develop and grow their startups has been missing from the market. Almaral and Liquido have now teamed up to create a unique combination of insight and knowledge in startup growth architecture and funding.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom